Interleukin-21 in cancer immunotherapy: Friend or foe?
C Stolfi, F Pallone, TT Macdonald… - …, 2012 - Taylor & Francis
Oncoimmunology, 2012•Taylor & Francis
Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and
Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is
also pro-inflammatory in many tissues and promotes colitis-associated colon cancer.
Understanding the biology of IL-21 in these different situations is needed to ensure maximal
therapeutic benefit.
Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is
also pro-inflammatory in many tissues and promotes colitis-associated colon cancer.
Understanding the biology of IL-21 in these different situations is needed to ensure maximal
therapeutic benefit.
Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit.
Taylor & Francis Online